Treatment and research lines for the patient with COVID-19. What do we have and where are we going?

Abstract

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents the most significant global public health crisis of this generation. From the beginning of the pandemic, several publications and on-line resources about different treatment lines have been done, and development effort in response to the COVID-19 pandemic to investigate potential therapies is unprecedented. Unfortunately, until now, there is not enough evidence to recommend any specific anti-COVID19 treatment. Randomized clinical trials and high-quality evidence, even in the middle of a pandemic, are needed. We provide a review of the latest published literature on the therapeutic strategies and current investigational lines for SARS-CoV-2.

Drugs for COVID-19: An Update

“…For this reason, both chloroquine and its hydroxyl derivative were widely used in many countries during the first wave of COVID-19. A first clinical trial in China reported significant improvements in over 100 cases of COVID-19 patients treated with chloroquine [ 57 ]. In other studies, it has also been shown that the combination of hydroxychloroquine with the antibiotic azithromycin increases the effectiveness of the treatment, compared to the administration of hydroxychloroquine alone [ 33 ].…”

Special consideration in the dosing of medications for patients with COVID-19 and acute kidney injury

“…We read with interest the authors' recommendation of prescribing and adjusting the dosage of therapeutic agents in patients with COVID-19 and concurrent renal impairment (1). Although the recommended dosage adjustment of a few COVID-19-specific pharmacological treatments had been based on clear cutoffs of renal function, we afraid that the recommended approach may be misleading, specifically for patients with COVID-19 and concurrent acute kidney injury.…”

The impact of COVID-19 on manuscript submissions to Pediatric Research

“…The emergence of COVID-19 as a global pandemic in early 2020 has led to pervasive changes in the social and occupational behavior of scientists and physician-scientists. Perhaps expectedly, there has been a surge in biological, epidemiological, and clinical publications pertaining to COVID-19 in the worldwide scientific community [1][2][3] . However, many researchers have had limited or no access to their regular place of work and are under (at least partial) mandatory or voluntary stay-at-home orders.…”